Coloplast delivered Q1 organic growth of 6% and EBIT growth 1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested ...

Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the ...

Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...

Coloplast shares fell more than 7% on Friday after the Danish medical-equipment maker posted a softer-than-expected start to its 2025/26 financial year, with grow ...

Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...